Sutro Biopharma Inc (STRO) ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food...

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian...

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company...

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

- Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities